Jefferies still bullish on Opko despite short call

|By:, SA News Editor

Jefferies is out with some commentary on Opko Health (OPK +5.2%) amid controversy surrounding a short thesis advanced by Lakewood Capital (see Lakewood's article on SA here).

"In our view, timely achievements of its laid-out milestones and future sales revenues meeting our expectations (albeit significantly lower than its noted market opportunities) would likely provide potential upside to current levels," analyst Eun Yang says.

Buy rating reiterated.

Price target is $11.50.